Rapid Image-Based Screening for Bioactive Compounds that Block SARS-CoV-2 Replication Cycle (UA20-225)

University of Arizona researchers have created a rapid image-based drug screening software platform for bioactive compounds that can block SARS-CoV-2 replication cycles. The invention utilizes a custom image processing algorithm that utilizes microscopy images to develop drug response profiles to identify lead compounds. This technology can also be used to neutralize antibodies, monobodies, or peptides.Background:Within the drug discovery process, lead compounds are chemical compounds that show desired biological or pharmacological activity and may initiate the development of a new clinically relevant compound. Lead compounds are commonly used as a starting point in drug design. With the advancement of technology, computer-aided drug design (CADD) has been incorporated into lead compound discovery within the drug discovery process. Since the severe acute respiratory syndrome SARS-CoV-2 (Coronavirus) has spread globally, there is a greater need to look for novel vaccines and drugs that alleviate and prevent contracting the virus. This includes identifying a possible lead bioactive compound that will block the coronavirus replication cycle to assist in the prevention and contamination of this current global pandemic.Learn more at https://bit.ly/UA20-225 Anne Spieth annes@tla.arizona.edu 520-626-1577

Related Blog

Smart, interactive desk

Get ready to take your space management game to the next level with the University of Glasgow’s innovative project! By combining the

Mechanical Hamstring™

University of Delaware Technology Overview This device was created to allow athletes who suffer a hamstring strain to return to the field

Join Our Newsletter

                                                   Receive Innovation Updates, New Listing Highlights And More